Brief: Genocea Introduces Gen-011, A Transformational T Cell Therapy Designed To Improve On Current Limitations Of Til Therapy
12/05/2020 23:07
May 12 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA INTRODUCES GEN-011, A TRANSFORMATIONAL T CELL
THERAPY
DESIGNED TO IMPROVE ON CURRENT LIMITATIONS OF TIL THERAPY
* GENOCEA BIOSCIENCES INC - TO ADVANCE GEN-011, WITH AN IND
FILING
WITHIN Q2 AND INITIAL CLINICAL DATA IN FIRST HALF OF 2021
Source text for Eikon: ID:nGNX8gBJg4
Further company coverage: GNCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc